Common medications in this class include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GLP-1/GIP receptor agonist
Their blood sugar effects are substantial: Semaglutide: Reduces A1c by 1.5-1.8% from baseline (Ozempic trials) Tirzepatide: Reduces A1c by 2.0-2.3% from baseline (SURPASS trials)
Studies suggest a correlation between using GLP-1 drugs and an increased risk of developing thyroid cancers
Further studies are needed to test the intermittent fasting from dawn to sunset in the prevention and treatment of metabolic syndrome-induced cancers
WB4-24, a non-peptide GLP-1 receptor agonist, demonstrated dose-dependent attenuation in mouse models of acute and chronic inflammatory nociception via the release of -endorphins from spinal microglia [17]